Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety
Masakazu Kanamori(Chugai Pharma (United States)), Hideaki Shimada(Chugai Pharma (United States))
Cited by 0
Related Papers
Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0